Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Surmodics Inc (SRDX)

Surmodics Inc (SRDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 594,072
  • Shares Outstanding, K 14,260
  • Annual Sales, $ 132,580 K
  • Annual Income, $ -1,540 K
  • 60-Month Beta 1.18
  • Price/Sales 4.49
  • Price/Cash Flow 53.29
  • Price/Book 4.81
Trade SRDX with:

Options Overview Details

View History
  • Implied Volatility 19.66% ( +3.65%)
  • Historical Volatility 3.52%
  • IV Percentile 2%
  • IV Rank 13.69%
  • IV High 78.20% on 10/30/23
  • IV Low 10.37% on 07/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 40
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 506
  • Open Int (30-Day) 516

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.31
  • Number of Estimates 2
  • High Estimate -0.31
  • Low Estimate -0.31
  • Prior Year 0.52
  • Growth Rate Est. (year over year) -159.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.58 +0.43%
on 07/19/24
42.44 -1.60%
on 07/09/24
-0.19 (-0.45%)
since 06/21/24
3-Month
25.17 +65.91%
on 04/30/24
42.44 -1.60%
on 07/09/24
+16.37 (+64.47%)
since 04/22/24
52-Week
25.17 +65.91%
on 04/30/24
42.44 -1.60%
on 07/09/24
+9.91 (+31.11%)
since 07/21/23

Most Recent Stories

More News
SurModics: Fiscal Q2 Earnings Snapshot

SurModics: Fiscal Q2 Earnings Snapshot

SRDX : 41.72 (+0.14%)
SurModics: Fiscal Q1 Earnings Snapshot

SurModics: Fiscal Q1 Earnings Snapshot

SRDX : 41.72 (+0.14%)
SurModics: Fiscal Q4 Earnings Snapshot

SurModics: Fiscal Q4 Earnings Snapshot

SRDX : 41.72 (+0.14%)
SurModics: Fiscal Q3 Earnings Snapshot

SurModics: Fiscal Q3 Earnings Snapshot

SRDX : 41.72 (+0.14%)
Why Shares of Surmodics Jumped This Week

The company gained FDA marketing approval for a drug-coated balloon that will help clear blocked arteries.

SRDX : 41.72 (+0.14%)
Why Shares of Surmodics Soared on Tuesday

An analyst upgrade gave the stock a boost.

SRDX : 41.72 (+0.14%)
SurModics: Fiscal Q2 Earnings Snapshot

SurModics: Fiscal Q2 Earnings Snapshot

SRDX : 41.72 (+0.14%)
Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March...

SRDX : 41.72 (+0.14%)
Surmodics Announces First Patient Enrolled in PROWL Registry Study Using the Pounceâ„¢ Thrombectomy System

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced enrollment of the first patient in PROWL, the Pounceâ„¢ Thrombectomy System Retrospective...

SRDX : 41.72 (+0.14%)
Surmodics to Report Second Quarter of Fiscal 2023 Financial Results on April 26

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2023 financial results...

SRDX : 41.72 (+0.14%)

Business Summary

Surmodics is a leading provider of medical device and In Vitro Diagnostics (IVD) technologies to the healthcare industry. It reports through two divisions: Medical Devices & IVD.'The Medical Devices segment comprises surface modification coating technologies to improve access, deliverability, and predictable...

See More

Key Turning Points

3rd Resistance Point 41.95
2nd Resistance Point 41.86
1st Resistance Point 41.76
Last Price 41.72
1st Support Level 41.57
2nd Support Level 41.48
3rd Support Level 41.38

See More

52-Week High 42.44
Last Price 41.72
Fibonacci 61.8% 35.84
Fibonacci 50% 33.81
Fibonacci 38.2% 31.77
52-Week Low 25.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar